XYP-317

N/A

Report date: 2025/01/26 17:54:41

Base Information

Drug NameXYP-317
Drug Alias NameAnti-HER2 MicAbody Antibody + Anti-MicAbody CAR T-Cell Therapy (Xyphos)anti-HER2 convertibleCAR-T cell therapy (Xyphos)cCAR-T-Cell Therapy (Xyphos)Anti-HER2 CAR T-Cell Therapy (Xyphos)XYP-317
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXyphos
China Registration ClassN/A

Develop Information

Active CompaniesXyphos
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A